Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top
Cut 89% covid risks: any investing plan for recovery stocks?
Views 115K Contents 89

A Breakthrough in Covid 19 Antiviral Pills

This year, two giants pharmaceutical companies, $Merck & Co (MRK.US)$ and $Pfizer (PFE.US)$ have announced their clinical findings on the use of antiviral pills for the treatment of Covid 19 and the Delta Varient. These antiviral pills are Molnupiravir, from $Merck & Co (MRK.US)$ and Paxlovid, from $Pfizer (PFE.US)$. Based on the companies’ clinical trials, both these two drugs help to reduce the coronavirus ability to replicate and hence slow down the disease process. They hold the promise of cutting down the risk of severe Covid 19 ailments, hospitalisation stays and even deaths, and if being taken at the early onsets of infection. $Pfizer (PFE.US)$ statistics showcases that Paxlovid can effectively treat 89% of the acutely hospitalised patients, which is a significant indicator for a good percentage of the patients’ recovery. Moreover, oral medications have greater convenience over the administration of intravenous medications.
Therefore, will there be a breakthrough in the era of the antiviral pills and which pharmaceutical company will emerge as the winner? Irregardless, of which company to emerge as the game changer, the vital role is for the antiviral 💊 not only to work, but most importantly, to work Effectively, in order to save the lives of the countless Covid 19 victims worldwide.
At this moment, their efficacies and side effects are not clearly defined yet. However, it will certainly open up a new chapter in the history of Healthcare if one of these two medications works, or even better still if both can prove their worth.
Obviously, the price for a treatment course is just as important. Molnupiravir is priced at US $700 for a five days’ treatment cost. $Pfizer (PFE.US)$ has not revealed the Paxlovid’s pricing yet, but it has promised the consumers of an affordable cost. Recently, $Pfizer (PFE.US)$ shares prices have surged upwards, since CEO, Albert Bourla’s announcement of the favourable research findings. Moving forward, I can anticipate that $Pfizer (PFE.US)$ shares will even be more bullish once US, FDA has approved of its use as an antiviral pill.
$Moderna (MRNA.US)$
$Novavax (NVAX.US)$
$BioNTech (BNTX.US)$
$Johnson & Johnson (JNJ.US)$
$Merck & Co (MRK.US)$

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
1
27
+0
6
Translate
Report
130K Views
Comment
Sign in to post a comment